AGL 8.15 Decreased By ▼ -0.15 (-1.81%)
ANL 11.09 Increased By ▲ 0.14 (1.28%)
AVN 83.70 Increased By ▲ 4.00 (5.02%)
BOP 5.85 Increased By ▲ 0.10 (1.74%)
CNERGY 5.65 Increased By ▲ 0.01 (0.18%)
EFERT 80.22 Increased By ▲ 0.86 (1.08%)
EPCL 67.28 Decreased By ▼ -0.20 (-0.3%)
FCCL 15.20 Increased By ▲ 0.31 (2.08%)
FFL 7.23 Increased By ▲ 0.53 (7.91%)
FLYNG 8.06 Increased By ▲ 0.90 (12.57%)
GGGL 12.00 Increased By ▲ 0.40 (3.45%)
GGL 17.71 Increased By ▲ 0.20 (1.14%)
GTECH 8.78 Increased By ▲ 0.43 (5.15%)
HUMNL 7.23 Increased By ▲ 0.06 (0.84%)
KEL 3.74 Increased By ▲ 0.60 (19.11%)
LOTCHEM 32.10 Decreased By ▼ -3.10 (-8.81%)
MLCF 29.00 Increased By ▲ 0.65 (2.29%)
OGDC 86.05 Decreased By ▼ -1.65 (-1.88%)
PAEL 17.40 Increased By ▲ 0.77 (4.63%)
PIBTL 6.30 Increased By ▲ 0.25 (4.13%)
PRL 19.10 Decreased By ▼ -0.36 (-1.85%)
SILK 1.19 Increased By ▲ 0.05 (4.39%)
TELE 12.25 Increased By ▲ 0.84 (7.36%)
TPL 9.18 Decreased By ▼ -0.02 (-0.22%)
TPLP 20.70 Increased By ▲ 0.45 (2.22%)
TREET 26.95 Decreased By ▼ -0.15 (-0.55%)
TRG 97.75 Increased By ▲ 1.55 (1.61%)
UNITY 23.00 Increased By ▲ 2.15 (10.31%)
WAVES 14.10 Increased By ▲ 0.20 (1.44%)
WTL 1.31 Decreased By ▼ -0.03 (-2.24%)
BR100 4,389 Increased By 113.1 (2.65%)
BR30 16,099 Increased By 305.6 (1.94%)
KSE100 43,677 Increased By 804.8 (1.88%)
KSE30 16,532 Increased By 312.9 (1.93%)
World

Moderna completes filing process for full approval of COVID-19 vaccine

  • Moderna's completed submission includes data from a late-stage study that showed 93% vaccine efficacy
Published August 25, 2021

Moderna Inc has completed the real-time review process needed for a full approval for its COVID-19 vaccine in people aged 18 years and above, the company said on Wednesday.

The news comes within days of US regulators granting full approval to Pfizer Inc/BioNTech SE's COVID-19 vaccine, developed with the same mRNA technology as Moderna's.

Messenger RNA (mRNA) vaccines prompt the human body to make a protein that is part of the pathogen, triggering an immune response.

US health officials expect full approval for COVID-19 vaccines will help win over vaccine skeptics and prompt more state and local governments, as well as private employers, to impose vaccine mandates.

Moderna's completed submission includes data from a late-stage study that showed 93% vaccine efficacy, even through six months after administration of the second dose, the company said in a statement.

As part of the submission, Moderna has requested a priority review designation for its vaccine, currently available in the United States for people aged 18 and older under an emergency use authorization (EUA) granted by the FDA in December.

So far, the company has released more than 300 million doses of the vaccine to the US government.

Comments

Comments are closed.